Organogenesis Holdings (ORGO) Preferred Stock Liabilities (2016 - 2026)
Organogenesis Holdings (ORGO) posted quarterly Preferred Stock Liabilities of $136.8 million for Q1 2026, up 9.29% year-over-year from $125.2 million in Q1 2025, and up 2.24% quarter-over-quarter from $133.8 million in Q4 2025.
Organogenesis Holdings (ORGO) Preferred Stock Liabilities (2016 - 2026) Analysis & Trends
Organogenesis Holdings' Preferred Stock Liabilities history runs 6 years deep, the most recent figure standing at $136.8 million for Q1 2026.
- In Q1 2026, Preferred Stock Liabilities rose 9.29% year-over-year to $136.8 million; the TTM figure through Mar 2026 stood at $136.8 million (up 9.29% YoY), while the FY2025 annual figure was $133.8 million, up 9.29% from the prior year.
- Preferred Stock Liabilities for Q1 2026 stood at $136.8 million, up from $133.8 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $136.8 million in Q1 2026, with the low at $122.4 million in Q4 2024.
- The 3-year median for Preferred Stock Liabilities is $129.4 million (2025), against an average of $129.5 million.
- The sharpest annual moves came in 2025 and 2026: Preferred Stock Liabilities climbed 9.29% in 2025, then rose 9.29% in 2026.
- Organogenesis Holdings' Preferred Stock Liabilities stood at $122.4 million in 2024, then advanced by 9.29% to $133.8 million in 2025, then increased by 2.24% to $136.8 million in 2026.
- Business Quant data shows ORGO's Preferred Stock Liabilities at $136.8 million in Q1 2026, $133.8 million in Q4 2025, and $130.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Organogenesis Holdings | 238.69 Mn | 191.85 Mn | 20.08 Mn | 139.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 139.86 Mn |
| Mar 31, 2026 | 136.79 Mn |
| Dec 31, 2025 | 133.79 Mn |
| Sep 30, 2025 | 130.85 Mn |
| Jun 30, 2025 | 127.98 Mn |
| Mar 31, 2025 | 125.17 Mn |
| Dec 31, 2024 | 122.42 Mn |
| Sep 30, 2018 | 298.17 Mn |
| Jun 30, 2018 | 293.23 Mn |
| Mar 31, 2018 | 292.88 Mn |
| Dec 31, 2017 | 6.76 Mn |
| Sep 30, 2017 | 293.51 Mn |
| Jun 30, 2017 | 295.63 Mn |
| Mar 31, 2017 | 295.25 Mn |
| Dec 31, 2016 | 295.11 Mn |